Understanding PSA Levels & The PSA Test | HALO Precision Diagnostics
18F-rhPSMA-7 PET for the Detection of Biochemical Recurrence of Prostate Cancer After Curative-Intent Radiation Therapy: A Bicentric Retrospective Study | Journal of Nuclear Medicine
Patient characteristics of 156 patients with PSA levels under 10 ng/mL. | Download Table
SciELO - Brasil - Importance of prostate-specific antigen (PSA) as a predictive factor for concordance between the Gleason scores of prostate biopsies and RADICAL prostatectomy specimens Importance of prostate-specific antigen (PSA) as
Reevaluating PSA Testing Rates in the PLCO Trial | NEJM
xmlinkhub
Biochemical recurrence after radical prostatectomy according to nadir prostate specific antigen value | PLOS ONE
ROC curves for diagnosis of PsA, AS, and RA. p-values < 0.05 are... | Download Scientific Diagram
Roc-Analysis of different PSA-ranges: includes tPSA-range 4-10 ng/ml. | Download Scientific Diagram
Low detectable PSA after prostatectomy – watch or treat? | THE "NEW" PROSTATE CANCER INFOLINK
Ethnicity Is an Independent Determinant of Age-Specific PSA Level: Findings from a Multiethnic Asian Setting | PLOS ONE
Usefulness of ultra‑sensitive prostate‑specific antigen following radical prostatectomy
Biochemical recurrence after radical prostatectomy according to nadir prostate specific antigen value | PLOS ONE
Percent Free Prostate-Specific Antigen: Entering a New Era in the Detection of Prostate Cancer
Table 5.5 from Prostate Specific Antigen (PSA) growth curves: A method to improve prostate cancer screening | Semantic Scholar
Treatment Outcomes from 68Ga-PSMA PET/CT–Informed Salvage Radiation Treatment in Men with Rising PSA After Radical Prostatectomy: Prognostic Value of a Negative PSMA PET | Journal of Nuclear Medicine
225Ac-PSMA-617 in chemotherapy-naive patients with advanced prostate cancer: a pilot study.
Mean prostate-specific antigen (PSA) levels of various groups. aP | Download Scientific Diagram
PSA Relapse after Surgery
Real-world comparison of Docetaxel versus new hormonal agents in combination with androgen-deprivation therapy in metastatic hormone-sensitive prostate cancer descrying PSA Nadir ≤ 0.05 ng/ml as marker for treatment response | SpringerLink
